Infographics
Click any card to open the full infographic.
GLP-1 Bait & Switch: How the Affordable Version Got Shut Down
For two years, Ozempic/Wegovy/Zepbound were legally available compounded for ~$200/mo because of an official shortage. Then the FDA declared the shortage over, the cheap versions were shut down by law, and prices snapped back to $1,000+. The full timeline, both sides (safety vs profit), the lawsuit, and what to do if you got cut off — in plain English.
DMSO: What It Actually Does
A cheap, clear liquid that soaks straight through skin — FDA-approved for exactly one bladder condition, used off-label by many for joint and muscle pain. The honest picture in plain English: what's proven, what's hopeful, the garlic-breath, the pharma-grade-only safety rule, and cost vs proven alternatives.
Retatrutide: The Triple-Agonist Phase 3 Just Confirmed
Eli Lilly's investigational GLP-1 / GIP / glucagon agonist — 28.3% body weight loss at 80 weeks in Phase 3 TRIUMPH-1 (May 2026). Phase 2 + 3 trial data, head-to-head vs semaglutide and tirzepatide, side-effect profile, FDA approval timeline, and what the principal investigator (Dr. Ania Jastreboff, Yale) actually says.
BPC-157: What the Research Actually Shows
Peer-reviewed evidence, community protocols, regulatory position, and cost vs alternatives — layered honestly. <30 published human subjects, 0 placebo RCTs, ~100+ preclinical studies.
Request a Topic
Got a health topic, compound, supplement, or peptide you want covered with the same evidence-honest treatment? Send a note — if it's a topic that fits the format, it gets built and added to the library.
Request an Infographic Topic →